ABOUT THIS DESK
Who Writes Peptide Medicine NY, and Why It Reads Like This
An independent literature digest — not a clinic, not a pharmacy, not a sales page.
What this site is
Peptide Medicine NY is an independent editorial digest of published research on four peptides — GHK-Cu, PT-141, retatrutide, and semaglutide. It exists because these four keep coming up in the same conversation: a patient reads something online, brings it to a clinician, and the clinician needs a straight, sourced answer faster than a literature search allows. This site is that answer, written down.
It is not a clinic. It does not diagnose, prescribe, dispense, or sell any of the compounds it covers. It does not recommend a dose for anyone, under any circumstance — that decision belongs to a licensed clinician working with an actual patient, not a website. Every factual claim on this site traces to a specific study, trial, or regulatory document, listed by number on the references page. Where a claim is community-reported rather than clinically studied, it is labeled anecdotal, not clinical evidence, plainly, every time.
How to read this site
Each compound page follows the same arc: what it is, structurally; how it works, mechanistically; what the actual trial or study data shows, with citations; what people report experiencing outside of clinical settings, labeled as anecdotal; and what the literature specifically flags as a safety concern, also cited. The comparison page puts all four side by side on the dimensions that actually distinguish them — mechanism, evidence depth, regulatory status, and biggest caution.
A study result and a forum post are not the same kind of evidence, and this site never blends them without saying which is which. A Phase 2 trial and an FDA-approved label are not the same kind of evidence either, and the difference matters more than most marketing acknowledges. Reading in that order — mechanism, then evidence, then reported experience, then caution — is the fastest way to actually understand one of these compounds rather than just absorb someone else's conclusion about it.
Editorial stance
This site takes no position on whether any individual should use any of these compounds. That is not editorial neutrality for its own sake — it is a recognition that the right answer depends on a specific person's medical history, which a website cannot know and should not guess at. What this site will do is state plainly when evidence is strong, when it is thin, when it is Phase 2 instead of Phase 3, and when a claim is coming from a forum instead of a trial.
None of the compounds discussed here are sold, linked to a vendor, or promoted in any way on this site. No competitor brand names are referenced. This is a reading desk, not a storefront — and it stays that way on every page.